amlodipine besylate; indapamide; telmisartan · Azurity · NDA 219423
Widaplik
Earliest generic entry, as listed · earliest of 3 marketed strengths
23 Jan 2038
No marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 10322117, US 10799487, US 12465599, US 12673047.
Listed patents · 4 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10322117 | drug product · sets the listed date | 23 Jan 2038 |
| US 10799487 | drug product, use U-3448 · sets the listed date | 23 Jan 2038 |
| US 12465599 | drug product · sets the listed date | 23 Jan 2038 |
| US 12673047 | drug product · sets the listed date | 23 Jan 2038 |
Exclusivities · 1 unexpired
| NP | new product | 5 Jun 2028 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 3
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 219423 · 001 · RLD · discontinued | tablet, oral | EQ 1.25MG BASE;0.625MG;10MG | 23 Jan 2038 |
| 219423 · 002 · RLD · discontinued | tablet, oral | EQ 2.5MG BASE;1.25MG;20MG | 23 Jan 2038 |
| 219423 · 003 · RLD · discontinued | tablet, oral | EQ 5MG BASE;2.5MG;40MG | 23 Jan 2038 |